EAGAN, Minn.--(BUSINESS WIRE)-- Biothera today announced the appointment of Patricia Molloy, M.D. as Chief Medical Officer. In this role, Dr. Molloy is responsible for the clinical development of Imprime PGG®, the company’s immunotherapeutic oncology drug that is currently in multiple clinical trials for colorectal and lung cancer and chronic lymphocytic leukemia.
Dr. Molloy has more than 20 years of research experience with extensive late stage clinical development expertise in oncology, neurology and pediatrics. She was most recently Vice President, Global Medical Affairs and Strategic Consulting, for Premier Research Group. Previously Dr. Molloy held senior positions in oncology drug development and research at Cephalon, ImClone Systems, and Allergan.
Prior to working in the pharmaceutical industry, Dr. Molloy was Assistant Professor, Neuro-Oncology Group, and Director, Neurofibromatosis Group, Oncology Division at The Children’s Hospital of Philadelphia, the largest pediatric brain tumor center in the U.S. During that time, she was also an Assistant Professor of Neurology and Assistant Professor of Neurology in Pediatrics at the University of Pennsylvania School of Medicine. Dr. Molloy is a board certified neurologist with a fellowship in neuro-oncology.
“Dr. Molloy combines the experience of a practicing oncologist with clinical development leadership in successful oncology companies,” said Dan Conners, president of Biothera’s Pharmaceutical Group. “She is an excellent addition to the Biothera team.”
As Senior Medical Director at ImClone Systems, Dr. Molloy led the successful filing of a Biologics License Application (BLA) for cetuximab (Erbitux®) in the treatment of refractory colorectal cancer. At Cephalon, Dr. Molloy was Senior Medical Director Oncology/Neurology and led the bendamustine (Treanda®) program, including the design and implementation of clinical trials in the first-line treatment of advanced indolent NHL and mantle cell lymphoma as well as relapsed/refractory multiple myeloma.
Dr. Molloy received her doctorate from the University of Pennsylvania School of Medicine.
About Imprime PGG®
Imprime PGG® is a novel immunomodulatory drug in development as a cancer therapy. Neutrophils are the most abundant immune cell in the body and normally responsible for pathogen killing, but not anti-tumor activity. In preclinical cancer models, however, Imprime PGG has been shown to bind to neutrophils and harness their killing ability to reduce tumor growth and enhance long-term survival. This targeted mechanism is synergistic with multiple anti-tumor monoclonal antibodies, demonstrating the potential to improve patient outcomes in a wide range of cancer indications. Imprime PGG is currently being evaluated in a Phase III trial in KRAS wild type colorectal cancer and multiple Phase II clinical trials in non-small cell lung cancer and chronic lymphocytic leukemia. For more information, visit http://www.biothera.com/pharmaceutical/pipeline.html.
About Biothera, the Immune Health Company
Biothera is a U.S. biotechnology company dedicated to improving immune health. The company is developing pharmaceuticals that engage the innate immune system to fight cancer. (www.biothera.com)
Biothera, the Immune Health Company
David Walsh, 651-256-4606
KEYWORDS: United States North America Minnesota
INDUSTRY KEYWORDS: Health Biotechnology Clinical Trials Oncology Pharmaceutical